BACKGROUND: People with heart failure experience substantial disease burden that includes low exercise tolerance, poor health-related quality of life (HRQoL), increased risk of mortality and hospital admission, and high healthcare costs. The previous 2018 Cochrane review reported that exercise-based cardiac rehabilitation (ExCR) compared to no exercise control shows improvement in HRQoL and hospital admission amongst people with heart failure, as well as possible reduction in mortality over the longer term, and that these reductions appear to be consistent across patient and programme characteristics. Limitations noted by the authors of this previous Cochrane review include the following: (1) most trials were undertaken in patients with heart failure with reduced (< 45%) ejection fraction (HFrEF), and women, older people, and those with heart failure with preserved (≥ 45%) ejection fraction (HFpEF) were under-represented; and (2) most trials were undertaken in a hospital or centre-based setting.
OBJECTIVES: To assess the effects of ExCR on mortality, hospital admission, and health-related quality of life of adults with heart failure.
SEARCH METHODS: We searched CENTRAL, MEDLINE, Embase, CINAHL, PsycINFO and Web of Science without language restriction on 13 December 2021. We also checked the bibliographies of included studies, identified relevant systematic reviews, and two clinical trials registers.
SELECTION CRITERIA: We included randomised controlled trials (RCTs) that compared ExCR interventions (either exercise only or exercise as part of a comprehensive cardiac rehabilitation) with a follow-up of six months or longer versus a no-exercise control (e.g. usual medical care). The study population comprised adults (≥ 18 years) with heart failure - either HFrEF or HFpEF.
DATA COLLECTION AND ANALYSIS: We used standard Cochrane methods. Our primary outcomes were all-cause mortality, mortality due to heart failure, all-cause hospital admissions, heart failure-related hospital admissions, and HRQoL. Secondary outcomes were costs and cost-effectiveness. We used GRADE to assess the certainty of the evidence.
MAIN RESULTS: We included 60 trials (8728 participants) with a median of six months' follow-up. For this latest update, we identified 16 new trials (2945 new participants), in addition to the previously identified 44 trials (5783 existing participants). Although the existing evidence base predominantly includes patients with HFrEF, with New York Heart Association (NYHA) classes II and III receiving centre-based ExCR programmes, a growing body of trials includes patients with HFpEF with ExCR undertaken in a home-based setting. All included trials employed a usual care comparator with a formal no-exercise intervention as well as a wide range of active comparators, such as education, psychological intervention, or medical management. The overall risk of bias in the included trials was low or unclear, and we mostly downgraded the certainty of evidence of outcomes upon GRADE assessment. There was no evidence of a difference in the short term (up to 12 months' follow-up) in the pooled risk of all-cause mortality when comparing ExCR versus usual care (risk ratio (RR) 0.93, 95% confidence interval (CI) 0.71 to 1.21; absolute effects 5.0% versus 5.8%; 34 trials, 36 comparisons, 3941 participants; low-certainty evidence). Only a few trials reported information on whether participants died due to heart failure. Participation in ExCR versus usual care likely reduced the risk of all-cause hospital admissions (RR 0.69, 95% CI 0.56 to 0.86; absolute effects 15.9% versus 23.8%; 23 trials, 24 comparisons, 2283 participants; moderate-certainty evidence) and heart failure-related hospital admissions (RR 0.82, 95% CI 0.49 to 1.35; absolute effects 5.6% versus 6.4%; 10 trials; 10 comparisons, 911 participants; moderate-certainty evidence) in the short term. Participation in ExCR likely improved short-term HRQoL as measured by the Minnesota Living with Heart Failure (MLWHF) questionnaire (lower scores indicate better HRQoL and a difference of 5 points or more indicates clinical importance; mean difference (MD) -7.39 points, 95% CI -10.30 to -4.77; 21 trials, 22 comparisons, 2699 participants; moderate-certainty evidence). When pooling HRQoL data measured by any questionnaire/scale, we found that ExCR may improve HRQoL in the short term, but the evidence is very uncertain (33 trials, 37 comparisons, 4769 participants; standardised mean difference (SMD) -0.52, 95% CI -0.70 to -0.34; very-low certainty evidence). ExCR effects appeared to be consistent across different models of ExCR delivery: centre- versus home-based, exercise dose, exercise only versus comprehensive programmes, and aerobic training alone versus aerobic plus resistance programmes.
AUTHORS' CONCLUSIONS: This updated Cochrane review provides additional randomised evidence (16 trials) to support the conclusions of the previous 2018 version of the review. Compared to no exercise control, whilst there was no evidence of a difference in all-cause mortality in people with heart failure, ExCR participation likely reduces the risk of all-cause hospital admissions and heart failure-related hospital admissions, and may result in important improvements in HRQoL. Importantly, this updated review provides additional evidence supporting the use of alternative modes of ExCR delivery, including home-based and digitally-supported programmes. Future ExCR trials need to focus on the recruitment of traditionally less represented heart failure patient groups including older patients, women, and those with HFpEF.
BACKGROUND: This review aimed to compare the relative effectiveness of different exercise-based cardiac rehabilitation (ExCR) delivery modes (centre-based, home-based, hybrid and technology-enabled ExCR) on key heart failure (HF) outcomes: exercise capacity, health-related quality of life (HRQoL), HF-related hospitalisation and HF-related mortality.
METHODS AND RESULTS: Randomised controlled trials (RCTs) published through 20 June 2021 were identified from six databases, and reference lists of included studies. Risk of bias and certainty of evidence were evaluated using the Cochrane tool and Grading of Recommendations Assessment, Development and Evaluation, respectively. Bayesian network meta-analysis was performed using R. Continuous and binary outcomes are reported as mean differences (MD) and ORs, respectively, with 95% credible intervals (95% CrI). One-hundred and thirty-nine RCTs (n=18 670) were included in the analysis. Network meta-analysis demonstrated improvements in VO2peak following centre-based (MD (95% CrI)=3.10 (2.56 to 3.65) mL/kg/min), home-based (MD=2.69 (1.67 to 3.70) mL/kg/min) and technology-enabled ExCR (MD=1.76 (0.27 to 3.26) mL/kg/min). Similarly, 6 min walk distance was improved following hybrid (MD=84.78 (31.64 to 138.32) m), centre-based (MD=50.35 (30.15 to 70.56) m) and home-based ExCR (MD=36.77 (12.47 to 61.29) m). Incremental shuttle walk distance did not improve following any ExCR delivery modes. Minnesota living with HF questionnaire improved after centre-based (MD=-10.38 (-14.15 to -6.46)) and home-based ExCR (MD=-8.80 (-13.62 to -4.07)). Kansas City Cardiomyopathy Questionnaire was improved following home-based ExCR (MD=20.61 (4.61 to 36.47)), and Short Form Survey 36 mental component after centre-based ExCR (MD=3.64 (0.30 to 6.14)). HF-related hospitalisation and mortality risks reduced only after centre-based ExCR (OR=0.41 (0.17 to 0.76) and OR=0.42 (0.16 to 0.90), respectively). Mean age of study participants was only associated with changes in VO2peak.
CONCLUSION: ExCR programmes have broader benefits for people with HF and since different delivery modes were comparably effective for improving exercise capacity and HRQoL, the selection of delivery modes should be tailored to individuals' preferences.
Objectives. This systematic review aims to summarize the existing literature on Tai Chi randomized controlled trials (RCTs) and recommend Tai Chi exercise prescriptions for different diseases and populations. Methods. A systematic search for Tai Chi RCTs was conducted in five electronic databases (PubMed, Cochrane Library, EMBASE, EBSCO, and Web of Science) from their inception to December 2019. SPSS 20.0 software and Microsoft Excel 2019 were used to analyze the data, and the risk of bias tool in the RevMan 5.3.5 software was used to evaluate the methodological quality of RCTs. Results. A total of 139 articles were identified, including diseased populations (95, 68.3%) and healthy populations (44, 31.7%). The diseased populations included the following 10 disease types: musculoskeletal system or connective tissue diseases (34.7%), circulatory system diseases (23.2%), mental and behavioral disorders (12.6%), nervous system diseases (11.6%), respiratory system diseases (6.3%), endocrine, nutritional or metabolic diseases (5.3%), neoplasms (3.2%), injury, poisoning and certain other consequences of external causes (1.1%), genitourinary system diseases (1.1%), and diseases of the eye and adnexa (1.1%). Tai Chi exercise prescription was generally classified as moderate intensity. The most commonly applied Tai Chi style was Yang style (92, 66.2%), and the most frequently specified Tai Chi form was simplified 24-form Tai Chi (43, 30.9%). 12 weeks and 24 weeks, 2-3 times a week, and 60 min each time was the most commonly used cycle, frequency, and time of exercise in Tai Chi exercise prescriptions. Conclusions. We recommend the more commonly used Tai Chi exercise prescriptions for different diseases and populations based on clinical evidence of Tai Chi. Further clinical research on Tai Chi should be combined with principles of exercise prescription to conduct large-sample epidemiological studies and long-term prospective follow-up studies to provide more substantive clinical evidence for Tai Chi exercise prescriptions.
ANTECEDENTES: Muchas personas de mediana edad y de edad avanzada tienen más de una condición crónica. Por lo tanto, es importante para la síntesis de la efectividad de las intervenciones a través de varias comorbilidades. El objetivo de esta revisión sistemática fue resumir las pruebas actuales sobre la eficacia de Tai Chi en individuos con cuatro condiciones crónicas comunes del cáncer, la osteoartritis (OA), insuficiencia cardiaca (IC) y la enfermedad pulmonar obstructiva crónica (EPOC).
MÉTODOS: 4 bases de datos (MEDLINE, EMBASE, CINAHL y SPORTDiscus) en busca de artículos originales. Dos revisores de forma independiente los títulos y resúmenes, y luego llevado a cabo exámenes de texto completo, evaluación de calidad y, finalmente, de extracción de datos. 33 estudios cumplieron los criterios de inclusión. Los meta-análisis se realizaron en los síntomas específicos de la enfermedad, los resultados fisiológicos y de rendimiento físico de cada condición crónica. Los análisis de subgrupos en los síntomas específicos de la enfermedad fueron llevadas a cabo por la categorización de los estudios en subgrupos en función del tipo de grupos de comparación.
RESULTADOS: Los meta-análisis mostraron que el Tai Chi mejora o se mostró una tendencia a mejorar los resultados físicos de rendimiento, incluyendo 6 minutos a pie (6MWD) y la fuerza de los extensores de la rodilla, en la mayoría o todas las cuatro condiciones crónicas. Tai Chi también mejoró los síntomas específicos de la enfermedad de dolor y rigidez en la OA.
Conclusiones: Los resultados demostraron un efecto favorable o tendencia de Tai Chi para mejorar el rendimiento físico y demostraron que este tipo de ejercicio podría ser realizado por personas con diferentes enfermedades crónicas, incluyendo EPOC, HF y OA.
OBJETIVO: Actualizar la revisión sistemática de Cochrane para la rehabilitación cardíaca (RC) basada en ejercicio para la insuficiencia cardíaca.
MÉTODOS: Se realizó una revisión sistemática y metanálisis de ensayos controlados aleatorizados. MEDLINE, EMBASE y la Biblioteca Cochrane fueron exploradas hasta Enero de 2013. Ensayos con 6 o más meses de seguimiento fueron incluidos si evaluaron los efectos de las intervenciones de ejercicio solas o como un complemento de un amplio programa de RC comparado con un control sin ejercicio.
RESULTADOS: 33 ensayos fueron incluidos con 4740 participantes predominantemente con una fracción de eyección reducida (<40%) y clase II y III de la New York Heart Association. En comparación con los controles, mientras no hubo diferencia en la mortalidad por todas las causas combinada entre RC con ejercicio con un seguimiento de 1 año (riesgo relativo (RR) 0.93; 95% IC 0.69 a 1.27, p=0.67), hubo una tendencia hacia la reducción en ensayos con un seguimiento mayor a 1 año (RR 0.88; 0.75 a 1.02, 0.09). RC con ejercicio redujo el riesgo total (RR 0.75; 0.62 a 0.92, 0.005) y hospitalización específica por insuficiencia cardíaca (RR 0.61; 0.46 a 0.80, 0.0004) y resultó en una importante mejora clínica en el cuestionario de Minnesota Living with Heart Failure (diferencia media: -5.8 puntos, -9.2 a -2.4, 0.0007). Un análisis univariado de metarregresión mostró que estos beneficios fueron independientes del tipo de dosis o ejercicio de RC, y la duración del seguimiento, calidad o fecha de la publicación.
CONCLUSIONES: Esta revisión actualizada de Cochrane muestra que las mejoras en hospitalización y calidad de vida relacionada a la salud con RC basada en ejercicio parece ser consistente entre los pacientes sin importar las características del programa de RC y puede reducir la mortalidad a largo plazo. Se necesita un metanálisis con datos de participantes individuales para proveer evidencia confirmatoria sobre la importancia de un subgrupo de pacientes y características del nivel del programa (ej, dosis de ejercicio) en el resultado.
OBJETIVO: Se pretende llevar a cabo una revisión sistemática para evaluar los efectos de las intervenciones sobre la depresión en adultos con insuficiencia cardíaca (IC).
MÉTODOS: Se publica, peer-reviewed, Inglés-idioma, los futuros estudios de intervención fueron identificados en una búsqueda en Medline, CINAHL, PsychINFO, y las Bibliotecas Cochrane de revisiones sistemáticas y ensayos clínicos a partir de 1996 hasta agosto de 2011 y en las bibliografías pertinentes. Los estudios elegibles incluyeron pacientes con New York Heart Association clase funcional II y III HF con diseños experimentales o cuasi experimentales y preintervención y postintervención medidas de depresión. Los estudios elegibles eran no farmacológico con un tamaño de muestra <50, y los estudios de medicamentos sin un grupo de comparación.
Resultados: Veintitrés estudios experimentales y cuasi experimentales que incluyeron un total de 3564 personas con HF aportado evidencia sobre 6 tipos de intervenciones: inhibidores selectivos de la recaptación de serotonina (ISRS), un agente estimulante de la eritropoyesis, el ejercicio, los programas de control de enfermedades, complementaria y medicina alternativa (CAM), y una intervención multimodal de la terapia cognitivo-conductual y el ejercicio. Los estudios con ISRS examinado los efectos de la sertralina, paroxetina, citalopram y. Las intervenciones CAM incluido el tai chi, la terapia de relajación muscular progresiva, y la atención basada en la reducción del estrés.
CONCLUSIONES: La evidencia es fuerte que la farmacología y la CAM puede mejorar la depresión. Evidencia moderada apoya el uso de ejercicio. Un cuerpo fuerte de la evidencia indica que los programas de control de enfermedades no mejoran la depresión. Esta revisión no apoya el desarrollo de las directrices para el tratamiento de la depresión en personas con insuficiencia cardiaca porque la evidencia es insuficiente y, a veces, contradictorias.
People with heart failure experience substantial disease burden that includes low exercise tolerance, poor health-related quality of life (HRQoL), increased risk of mortality and hospital admission, and high healthcare costs. The previous 2018 Cochrane review reported that exercise-based cardiac rehabilitation (ExCR) compared to no exercise control shows improvement in HRQoL and hospital admission amongst people with heart failure, as well as possible reduction in mortality over the longer term, and that these reductions appear to be consistent across patient and programme characteristics. Limitations noted by the authors of this previous Cochrane review include the following: (1) most trials were undertaken in patients with heart failure with reduced (< 45%) ejection fraction (HFrEF), and women, older people, and those with heart failure with preserved (≥ 45%) ejection fraction (HFpEF) were under-represented; and (2) most trials were undertaken in a hospital or centre-based setting.
OBJECTIVES:
To assess the effects of ExCR on mortality, hospital admission, and health-related quality of life of adults with heart failure.
SEARCH METHODS:
We searched CENTRAL, MEDLINE, Embase, CINAHL, PsycINFO and Web of Science without language restriction on 13 December 2021. We also checked the bibliographies of included studies, identified relevant systematic reviews, and two clinical trials registers.
SELECTION CRITERIA:
We included randomised controlled trials (RCTs) that compared ExCR interventions (either exercise only or exercise as part of a comprehensive cardiac rehabilitation) with a follow-up of six months or longer versus a no-exercise control (e.g. usual medical care). The study population comprised adults (≥ 18 years) with heart failure - either HFrEF or HFpEF.
DATA COLLECTION AND ANALYSIS:
We used standard Cochrane methods. Our primary outcomes were all-cause mortality, mortality due to heart failure, all-cause hospital admissions, heart failure-related hospital admissions, and HRQoL. Secondary outcomes were costs and cost-effectiveness. We used GRADE to assess the certainty of the evidence.
MAIN RESULTS:
We included 60 trials (8728 participants) with a median of six months' follow-up. For this latest update, we identified 16 new trials (2945 new participants), in addition to the previously identified 44 trials (5783 existing participants). Although the existing evidence base predominantly includes patients with HFrEF, with New York Heart Association (NYHA) classes II and III receiving centre-based ExCR programmes, a growing body of trials includes patients with HFpEF with ExCR undertaken in a home-based setting. All included trials employed a usual care comparator with a formal no-exercise intervention as well as a wide range of active comparators, such as education, psychological intervention, or medical management. The overall risk of bias in the included trials was low or unclear, and we mostly downgraded the certainty of evidence of outcomes upon GRADE assessment. There was no evidence of a difference in the short term (up to 12 months' follow-up) in the pooled risk of all-cause mortality when comparing ExCR versus usual care (risk ratio (RR) 0.93, 95% confidence interval (CI) 0.71 to 1.21; absolute effects 5.0% versus 5.8%; 34 trials, 36 comparisons, 3941 participants; low-certainty evidence). Only a few trials reported information on whether participants died due to heart failure. Participation in ExCR versus usual care likely reduced the risk of all-cause hospital admissions (RR 0.69, 95% CI 0.56 to 0.86; absolute effects 15.9% versus 23.8%; 23 trials, 24 comparisons, 2283 participants; moderate-certainty evidence) and heart failure-related hospital admissions (RR 0.82, 95% CI 0.49 to 1.35; absolute effects 5.6% versus 6.4%; 10 trials; 10 comparisons, 911 participants; moderate-certainty evidence) in the short term. Participation in ExCR likely improved short-term HRQoL as measured by the Minnesota Living with Heart Failure (MLWHF) questionnaire (lower scores indicate better HRQoL and a difference of 5 points or more indicates clinical importance; mean difference (MD) -7.39 points, 95% CI -10.30 to -4.77; 21 trials, 22 comparisons, 2699 participants; moderate-certainty evidence). When pooling HRQoL data measured by any questionnaire/scale, we found that ExCR may improve HRQoL in the short term, but the evidence is very uncertain (33 trials, 37 comparisons, 4769 participants; standardised mean difference (SMD) -0.52, 95% CI -0.70 to -0.34; very-low certainty evidence). ExCR effects appeared to be consistent across different models of ExCR delivery: centre- versus home-based, exercise dose, exercise only versus comprehensive programmes, and aerobic training alone versus aerobic plus resistance programmes.
AUTHORS' CONCLUSIONS:
This updated Cochrane review provides additional randomised evidence (16 trials) to support the conclusions of the previous 2018 version of the review. Compared to no exercise control, whilst there was no evidence of a difference in all-cause mortality in people with heart failure, ExCR participation likely reduces the risk of all-cause hospital admissions and heart failure-related hospital admissions, and may result in important improvements in HRQoL. Importantly, this updated review provides additional evidence supporting the use of alternative modes of ExCR delivery, including home-based and digitally-supported programmes. Future ExCR trials need to focus on the recruitment of traditionally less represented heart failure patient groups including older patients, women, and those with HFpEF.
